BNP Paribas Financial Markets’s Crescent Biopharma CBIO Stock Holding History

BNP Paribas Financial Markets’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.5K	Sell	3,303 -12,391	-79%	-$242K	﹤0.01%	4807
2026 Q1	$288K	Buy	15,694 +12,109	+338%	+$139K	﹤0.01%	3881
2025 Q4	$42.5K	Buy	3,585 +3,581	+89,525%	+$45.6K	﹤0.01%	4759
2025 Q3	$48	Hold	4	–	–	﹤0.01%	5474
2025 Q2	$65	Sell	4 -1	-20%	-$21	﹤0.01%	5344
2025 Q1	$101	Hold	5	–	–	﹤0.01%	5254
2024 Q4	$120	Hold	5	–	–	﹤0.01%	5270
2024 Q3	$81	Hold	5	–	–	﹤0.01%	4070
2024 Q2	$135	Hold	5	–	–	﹤0.01%	3954
2024 Q1	$1.44K	Hold	5	–	–	﹤0.01%	3834
2023 Q4	$1.14K	Hold	5	–	–	﹤0.01%	3844
2023 Q3	$722	Hold	5	–	–	﹤0.01%	3767
2023 Q2	$837	Hold	5	–	–	﹤0.01%	3777
2023 Q1	$606	Hold	5	–	–	﹤0.01%	3711
2022 Q4	$1.46K	Hold	5	–	–	﹤0.01%	3764
2022 Q3	$265	Hold	5	–	–	﹤0.01%	4586
2022 Q2	$288	Hold	5	–	–	﹤0.01%	3976
2022 Q1	$548	Hold	5	–	–	﹤0.01%	4012
2021 Q4	$693	Hold	5	–	–	﹤0.01%	4085
2021 Q3	$1.19K	Hold	5	–	–	﹤0.01%	3857
2021 Q2	$1.26K	Sell	5 -146	-97%	-$37.2K	﹤0.01%	3927
2021 Q1	$45.4K	Buy	151 +80	+113%	+$28.7K	﹤0.01%	3635
2020 Q4	$26.5K	Sell	71 -15	-17%	-$5.26K	﹤0.01%	3787
2020 Q3	$26.3K	Buy	86 +68	+378%	+$26K	﹤0.01%	3737
2020 Q2	$6.87K	Sell	18 -87	-83%	-$24.6K	﹤0.01%	3874
2020 Q1	$23.9K	Buy	105 +65	+163%	+$24.8K	﹤0.01%	3859
2019 Q4	$20.9K	Sell	40 -15	-27%	-$8.12K	﹤0.01%	3992
2019 Q3	$23.5K	Buy	55 +17	+45%	+$10.9K	﹤0.01%	3880
2019 Q2	$45.4K	Sell	38 -33	-46%	-$39.5K	﹤0.01%	3481
2019 Q1	$88.3K	Buy	+71	New	+$81.3K	﹤0.01%	3197
2018 Q4	–	Sell	-11	Closed	-$15.8K	–	4368
2018 Q3	$15.8K	Hold	11	–	–	﹤0.01%	3516
2018 Q2	$17.7K	Buy	+11	New	+$18.9K	﹤0.01%	3546
2017 Q4	–	Sell	-1	Closed	-$1.01K	–	4253
2017 Q3	$1.01K	Hold	1	–	–	﹤0.01%	4091
2017 Q2	$804	Buy	+1	New	+$826	﹤0.01%	4122
2016 Q4	–	Sell	-8	Closed	-$5.37K	–	4180
2016 Q3	$5.37K	Buy	8 +4	+100%	+$3.06K	﹤0.01%	3374
2016 Q2	$2.94K	Buy	+4	New	+$2.76K	﹤0.01%	3417
2014 Q4	–	Sell	-2	Closed	-$1.3K	–	2478
2014 Q3	$1.3K	Sell	2 -4	-67%	-$3.24K	﹤0.01%	3973
2014 Q2	$4.96K	Buy	+6	New	+$5.97K	﹤0.01%	2589

Other funds holding CBIO

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

NCM

NEXTBio Capital Management Menlo Park, California $217M AUM

BNP Paribas Financial Markets's CBIO Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Crescent Biopharma (CBIO) stake by 79% in Q2 2026, selling an estimated $242K and leaving 3,303 shares worth $59.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4807.

BNP Paribas Financial Markets first reported a position in CBIO in Q2 2014 and has held it in 38 quarters since. The position peaked at $288K in Q1 2026. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

BNP Paribas Financial Markets held 3,303 shares of Crescent Biopharma worth $59.5K as of Q2 2026.
BNP Paribas Financial Markets sold 12,391 Crescent Biopharma shares in Q2 2026, an estimated $242K.
Crescent Biopharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4807 holding.
BNP Paribas Financial Markets first reported a position in Crescent Biopharma in Q2 2014 and has held it in 38 quarters since.
BNP Paribas Financial Markets's Crescent Biopharma position peaked at $288K in Q1 2026.
70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.